FDA Approval of argenx Product VYVGART Hytrulo for Patients with CIDP

argenx in the NEWS
argenx SE (ARGX) announced that the U.S. FDA has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only neonatal Fc receptor (FcRn) blocker . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.